News
Google News
More headlines & perspectives

Survodutide trial shows weight loss and liver fat reduction

Top news

WSJ

Zealand Pharma Shares Slide After Boehringer Study Shows Obesity Shot’s Side Effects

By Adria Calatayud
Reuters

Boehringer-Zealand's obesity drug shows promise in cutting visceral, liver fat

By Bhanvi Satija
Yahoo Finance

A Weight-Loss Rival Just Crashed 23%. Why That's Great News for Eli Lilly and Novo Nordisk.

By Bram Berkowitz
Nature

Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial

By Daniel Mazo, Elena Startseva & Arun J Sanyal, Mbbs MD

All coverage

Fierce Biotech

ADA: Boehringer execs claim survodutide tolerability 'consistent' with class despite phase 3 update

By Fraiser Kansteiner
CNBC

Weight loss drug maker sinks 23% after new safety data spooks investors

By Elsa Ohlen
MarketWatch

Zealand Pharma loses a fifth of its value as many users gave up taking weight-loss drug during trial

By Steve Goldstein
Endpoints News

Nearly 1 in 5 patients quit Boehringer and Zealand’s obesity shot over side effects

By Elizabeth Cairns
Managed Healthcare Executive

Lee Kaplan, M.D., discusses the metabolic case for survodutide | ADA 2026

By Rose Mcnulty
HCPLive

Why Weight Loss Percentage Isn't the Only Metric That Matters

VCU Health

New study reveals turbocharged GLP-1 drug helps shed body weight and fat in the liver

By A.J. Hostetler
Pharmacy Times

ADA 2026: Survodutide Cuts Visceral Fat and Normalizes Liver Fat in MASLD. Here's What the Data Mean for Metabolic Risk

MedPage Today

Tolerability Concerns for GLP-1/Glucagon Agonist in Obesity, MASLD

By Kristen Monaco
The Clinical Trial Vanguard

Reading the SYNCHRONIZE-MASLD Phase 3 Trial Publication Closely

By Moe Alsumidaie
PharmaTimes

Survodutide trial data show targeted visceral and liver fat reductions

By John Pinching
PR Newswire

Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health

Medscape

Dual Incretin Agonist Survodutide Benefits Liver in Phase 3

By Miriam E. Tucker
pharmaphorum

ADA: Safety data offset efficacy for survodutide

AJMC

Emerging Data Suggest Survodutide Targets Liver Fat More Rapidly Than Weight Loss: Lee Kaplan, MD, PhD

statnews.com

New data may cast doubt on competitiveness of Boehringer’s obesity drug

By Elaine Chen
BioSpace

ADA: Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reduction

By Tristan Manalac
Bloomberg

Boehringer Pitches Muscle-Sparing Obesity Drug in Crowded Field

By Naomi Kresge & Sonja Wind
Biostock

Zealand Pharma's candidate takes aim at visceral fat

diagnosticimaging.com

What New Phase 3 MRI Findings Reveal About Survodutide in Patients with Obesity and MASLD

By Jeff Hall
EMJ

Boehringer posts mixed obesity drug phase 3 results

By Isabel O'brien
The Pharma Letter

Boehringer obesity drug shows fat loss gains but tolerability clouds ADA readout

Newswire Canada

Boehringer Ingelheim's survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic health in people living with obesity

medwatch.com

Analysts see difficult road ahead for Zealand Pharma's weight-loss candidate

Devdiscourse

Survodutide: A Potential Game-Changer in Obesity and Liver Disease Treatment

whbl.com

Zealand Pharma shares drop 25% after a quarter of patients quit obesity drug trial

By Stine Jacobsen & Bhanvi Satija
GuruFocus

Zealand Pharma (ZLDPF) Shares Plunge 26% Amid Side Effect Concer

TipRanks

Zealand Pharma announces Boehringer’s phase III results of survodutide

Investing.com India

Why is Zealand Pharma stock crashing today? By Investing.com

By Maria Ponnezhath
IndexBox

Zealand Pharma Shares Plunge on Servodutide Phase III Trial Safety Concerns - News and Statistics

Blockonomi

Zealand Pharma (ZEAL) Plummets 25% on Survodutide Tolerability Concerns

TechStock²

Zealand Pharma Shares Sink 25% After Trial Results

CoinCentral

Zealand Pharma (ZEAL) Stock Drops 25% After Obesity Drug Trial Shows High Drop-Out Rate

The Motley Fool

A Weight-Loss Rival Just Crashed 23%. Why That's Great News for Eli Lilly and Novo Nordisk.

By Bram Berkowitz
Yahoo Finance

Boehringer-Zealand's obesity drug shows promise in cutting visceral, liver fat

By Bhanvi Satija
Seeking Alpha

Boehringer's obesity drug cuts harmful belly and liver fat in late-stage trials

By Rob Williams
Koreabizwire

Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic health in people living with obesity

Managed Healthcare Executive

Survodutide cuts visceral fat by 34%, liver fat by 63% in phase 3 trials | ADA 2026

By Rose Mcnulty
AJMC

Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss

Investing.com

Zealand Pharma shares crash 24% as obesity drug side effects overshadow trial data

By Navamya Acharya
AOL.com

A Weight-Loss Rival Just Crashed 23%. Why That's Great News for Eli Lilly and Novo Nordisk.

By Bram Berkowitz
The Clinical Trial Vanguard

Survodutide Phase III trial shows 34% visceral fat, 63% liver fat reduction

By Jon Napitupulu
The Manila Times

Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic health in people living with obesity

Investing.com Canada

Why is Zealand Pharma stock crashing today? By Investing.com

By Maria Ponnezhath
Investing.com

Why is Zealand Pharma stock crashing today?

By Maria Ponnezhath
medwatch.com

One in five dropped out: Analyst predicts disappointment for Zealand Pharma following new weight-loss data

WTAQ

Boehringer-Zealand’s obesity drug shows promise in cutting visceral, liver fat

By Caroline Humer, Bhanvi Satija & Sanjeev Miglani
The Mighty 790 KFGO

Boehringer-Zealand’s obesity drug shows promise in cutting visceral, liver fat

By Caroline Humer, Bhanvi Satija & Sanjeev Miglani
WTVB

Boehringer-Zealand’s obesity drug shows promise in cutting visceral, liver fat

By Caroline Humer, Bhanvi Satija & Sanjeev Miglani
Search
Clear search
Close search
Google apps
Main menu